祖拉诺用于治疗产后抑郁症
Kristina M Deligiannidis1, Samantha Meltzer-Brody1, Bassem Maximos1
1Division of Women's Behavioral Health, Zucker Hillside Hospital, Northwell Health, New York (Deligiannidis); Feinstein Institutes for Medical Research, Northwell Health, Manhasset, N.Y. (Deligiannidis); Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (Deligiannidis); Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill (Meltzer-Brody); Maximos Obstetrics and Gynecology, League City, Tex. (Maximos); Department of Obstetrics and Gynecology, LCMC Health, New Orleans (Peeper); Department of Psychiatry, Massachusetts General Hospital, and Harvard Medical School, Boston (Freeman); Sage Therapeutics, Cambridge, Mass. (Lasser, Bullock, Li, Rana, Garcia, Doherty); Biogen, Cambridge, Mass. (Kotecha, Forrestal, Leclair).
祖拉诺在14天的口服治疗过程中显著改善了产后抑郁症 (PPD) 症状. 这种新型疗法耐受性良好,为PPD管理提供了潜在的新选择.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 产后抑郁症 (PPD) 是一个重要的产周并发症,影响着母亲和婴儿的福祉.
- 现有的PPD治疗方法可能存在局限性,需要新的治疗方法.
研究的目的:
- 评估Zuranolone的疗效和安全性,Zuranolone是一种口服GABAA受体调节剂,用于治疗严重的PPD.
- 在14天的治疗方案中评估祖拉诺对抑郁症状和整体临床改善的影响.
主要方法:
- 这是一项双盲,随机,安慰剂控制的第三期试验,涉及患有严重PPD的女性.
- 参与者接受了苏拉诺 (50毫克/天) 或安慰剂14天,在多个时间点进行评估,直到第45天.
- 主要终点:15日汉密尔顿抑郁评分表 (HAM-D) 分数的变化. 二级终点包括其他时间点的HAM-D和临床全球印象严重性 (CGI-S) 评分.
主要成果:
- 与安慰剂相比,祖拉诺隆治疗在第15天导致抑郁症状的统计学显著改善 (HAM-D得分变化:15.6比11.6).
- 显著的改善持续到第45天,在第15天CGI-S得分显著提高.
- 常见的不良事件包括昏昏欲睡,头和镇静;没有观察到严重的安全问题,如失去意识或增加自杀念头.
结论:
- 祖拉诺在减轻严重PPD患者抑郁症状方面表现出显著的有效性.
- 苏拉诺的口服14天治疗疗程通常耐受良好,这表明它作为PPD新型快速起作用疗法的潜力.
更多相关视频
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
Management of Insomnia
Depressive Disorders: MDD and Dysthymia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Psychosis: Goals of Pharmacotherapy
Depression: Overview
